Redox Status and Exercise Training-induced Adaptations

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-45
SponsorUniversity of Thessaly

About this trial

Excess fat accumulation is a key feature of overweight and obesity that is mainly driven by nutrient overload and insufficient physical activity. White adipose tissue displays lipid overload and hypertrophy accompanied by macrophages infiltration, hypoxia, inflammation and excess production of reactive oxygen species (ROS). An inflammatory response and ROS production are also evident in other metabolism regulating tissues and organs such as skeletal muscle, liver, pancreas and hypothalamus, contributing to a chronic inflammatory state, redox status disturbances and metabolic complications. There is overwhelming evidence showing that adults with overweight/obesity exhibit lower glutathione (GSH) levels in blood erythrocytes, skeletal muscle cells and subcutaneous and visceral adipose tissue cells. GSH, a tripeptide consisting of the amino acids glutamate, cysteine and glycine, is the most abundant thiol-containing antioxidant in the human body and has been, recently, characterized as a novel therapeutic target for the treatment of numerous chronic diseases, due to its potent intracellular redox buffering capacity. Interestingly, lower GSH levels have been associated with diet-induced weight loss resistance, while enhancement of GSH levels through N-acetylcysteine (NAC) supplementation reduces markers of oxidative stress, inflammation, insulin resistance, hypertension, endothelia dysfunction and improves vitamin D metabolism. NAC is a thiol donor that elicits antioxidant effects by (i) directly scavenging ROS and (ii) providing reduced cysteine through deacetylation, which supports the biosynthesis of endogenous GSH via the activity of γ-glutamylcysteine synthase. The aim of this study is to investigate whether NAC supplementation can enhance the exercise training-induced improvements on physical fitness and metabolic health in adult men and women with overweight/obesity.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

BMI 25-35 kg/m2

Free of musculoskeletal injuries

Free of chronic non-communicable diseases

Do not receive any drug therapy

Disqualifiers

NAC intolerance

Bleeding disorders

Kidney disease

Asthma

Trial design

Design model

Parallel

Treatments tested in this trial

  • N Acetyl L Cysteine

    Dietary supplement

    Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 1200 mg N-acetylcysteine (2 pills x 600 mg/day ).

  • Placebo

    Dietary supplement

    Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 2 placebo pills/day.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: N-acetylcysteineExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in body weight (kg)

Time frame
At baseline, 6 weeks and 12 weeks
2

Change in waist circumference

Time frame
At baseline, 6 weeks and 12 weeks
3

Change in hip circumference

Time frame
At baseline, 6 weeks and 12 weeks
4

Change in fat mass (kg)

Fat mass will be assessed through dual energy X-ray absorptiometry (DXA)

Time frame
At baseline, 6 weeks and 12 weeks

Secondary outcomes

1

Change in dietary intake

Dietary intake will be monitored through diet recalls

Time frame
At baseline, 6 weeks and 12 weeks
2

Change in total number of steps

Total number of steps performed per day will be assessed by using accelerometers

Time frame
At baseline, 6 weeks and 12 weeks
3

Change in time spent in moderate-to-vigorous physical activity

The time spent in moderate-to-vigorous physical activity per day will be assessed by using accelerometers

Time frame
At baseline, 6 weeks and 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.